Authors’ contributions
ADVERSE EVENTS
NN, TA, AWMW, PNR and JT were responsible for the initiation and development of the trial. NR reported renal biopsies. NN, PNR and JT are involved in the eligibility determination process. DDW, NR, and APDA monitored treatments and adverse events. RK, HA and ZB performed the statistical analysis. ZB developed the manuscript. All authors read and approved the final manuscript.